SwePub
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:lup.lub.lu.se:a8416386-ad1a-470a-87dc-aa039af2033a"
 

Sökning: onr:"swepub:oai:lup.lub.lu.se:a8416386-ad1a-470a-87dc-aa039af2033a" > Interval breast can...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00005382naa a2200505 4500
001oai:lup.lub.lu.se:a8416386-ad1a-470a-87dc-aa039af2033a
003SwePub
008220228s2022 | |||||||||||000 ||eng|
009oai:prod.swepub.kib.ki.se:149687968
0247 a https://lup.lub.lu.se/record/a8416386-ad1a-470a-87dc-aa039af2033a2 URI
0247 a https://doi.org/10.1016/j.ejca.2021.12.0032 DOI
0247 a http://kipublications.ki.se/Default.aspx?queryparsed=id:1496879682 URI
040 a (SwePub)lud (SwePub)ki
041 a engb eng
042 9 SwePub
072 7a art2 swepub-publicationtype
072 7a ref2 swepub-contenttype
1001 a Ugalde-Morales, Emiliou Karolinska Institutet,Karolinska Institute4 aut
2451 0a Interval breast cancer is associated with interferon immune response
264 1b Elsevier BV,c 2022
300 a 12 s.
520 a Background: The aggressive nature of breast cancers detected between planned mammographic screens, so-called interval cancers, remains elusive. Here, we aim to characterise underlying molecular features of interval cancer. Methods: From 672 patients with invasive breast cancer, we analysed gene expression differences between 90 ‘true’ interval cancer cases (i.e. women with low-dense breasts defined as per cent mammographic density <25%) and 310 screen-detected tumours while accounting for PAM50 subtypes and thus overall tumour aggressiveness. We computed an interval cancer gene expression profile (IC-Gx) in a total of 2270 breast tumours (regardless of interval cancer status) and tested for association with expression-based immune subtypes in breast cancer. In addition, we investigated the contribution of inherited and somatic genetic variants in distinct features of interval cancer. Results: We identified 8331 genes nominally associated with interval cancer (P-value < 0.05, fold-change > 1.5). Gene set enrichment analysis showed immune-related pathways as key processes altered in interval cancer. Our IC-Gx, based on 47 genes with the strongest associations (false discovery rate < 0.05), was found to be associated mainly with immune subtypes involving interferon response. We isolated an interaction network of interval cancer and interferon genes for which a significant load of somatic and germline variants in class I interferon genes was observed. Conclusion: We identified novel molecular features of interval breast cancer highlighting interferon pathways as a potential target for prevention or treatment.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng
653 a Interferon immune response
653 a Interval breast cancer
653 a Mammographic density
653 a PAM50 subtypes
7001 a Grassmann, Felixu Karolinska Institutet,Karolinska Institute,Health and Medical University4 aut
7001 a Humphreys, Keithu Karolinska Institutet,Karolinska Institute4 aut0 (Swepub:lu)med-khu
7001 a Li, Jingmeiu Karolinska Institute,National University of Singapore,A*Star, Genome Institute of Singapore (GIS)4 aut
7001 a Eriksson, Mikaelu Karolinska Institutet,Karolinska Institute4 aut
7001 a Tobin, Nicholas P.u Karolinska Institutet,Karolinska Institute4 aut0 (Swepub:lu)med-npt
7001 a Lindström, Linda S.u Karolinska Institutet,Karolinska Institute4 aut
7001 a Vallon-Christersson, Johanu Lund University,Lunds universitet,Create Health,Annan verksamhet, LTH,Lunds Tekniska Högskola,Bröstcancer-genetik,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,LUCC: Lunds universitets cancercentrum,Övriga starka forskningsmiljöer,Other operations, LTH,Faculty of Engineering, LTH,Breastcancer-genetics,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine,LUCC: Lund University Cancer Centre,Other Strong Research Environments4 aut0 (Swepub:lu)onk-jvc
7001 a Borg, Åkeu Lund University,Lunds universitet,Create Health,Annan verksamhet, LTH,Lunds Tekniska Högskola,Bröstcancer-genetik,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Familjär bröstcancer,Forskargrupper vid Lunds universitet,LUCC: Lunds universitets cancercentrum,Övriga starka forskningsmiljöer,Other operations, LTH,Faculty of Engineering, LTH,Breastcancer-genetics,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine,Familial Breast Cancer,Lund University Research Groups,LUCC: Lund University Cancer Centre,Other Strong Research Environments4 aut0 (Swepub:lu)onk-abo
7001 a Hall, Peru Karolinska Institutet,Karolinska Institute4 aut
7001 a Czene, Kamilau Karolinska Institutet,Karolinska Institute4 aut
7102 a Karolinska Institutetb Karolinska Institute4 org
7730 t European Journal of Cancerd : Elsevier BVg 162, s. 194-205q 162<194-205x 0959-8049x 1879-0852
8564 u http://dx.doi.org/10.1016/j.ejca.2021.12.003x freey FULLTEXT
8564 u http://www.ejcancer.com/article/S0959804921012582/pdf
8564 8u https://lup.lub.lu.se/record/a8416386-ad1a-470a-87dc-aa039af2033a
8564 8u https://doi.org/10.1016/j.ejca.2021.12.003
8564 8u http://kipublications.ki.se/Default.aspx?queryparsed=id:149687968

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy